Paxlovid did not help long Covid, study finds

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-01 • Permanent link

Generally, investors are breathing a sigh of relief after a new study published in the Journal of the American Medical Association found that Paxlovid, a treatment for COVID-19, did not provide significant relief for long-term COVID-19 symptoms. The study, conducted by researchers at the University of California, San Francisco, involved over 1,000 participants who were treated with Paxlovid for at least 28 days. The results showed that the treatment had no significant impact on long-term symptoms, including fatigue, brain fog, and muscle pain.

Significantly, the findings of this study have the potential to impact the pharmaceutical industry, as investors had been eagerly awaiting news on the effectiveness of Paxlovid in treating long-term COVID-19 symptoms. The study's results could also influence the development of new treatments for long-term COVID-19, as researchers may need to explore alternative approaches to managing symptoms. For consumers, the study's findings may provide a sense of relief, as they may no longer need to worry about Paxlovid being a viable treatment option for long-term symptoms.

Historically, the development of treatments for long-term COVID-19 symptoms has been a complex and challenging process. Since the onset of the pandemic, researchers have been working tirelessly to develop effective treatments, but many have been met with limited success. The study's findings are a significant step forward in this effort, as they provide valuable insights into the effectiveness of Paxlovid in treating long-term symptoms. Experts in the field are already calling for further research to be conducted, in order to better understand the causes and consequences of long-term COVID-19 symptoms.

Ultimately, the study's findings have significant implications for the future of COVID-19 treatment and management. Researchers will need to carefully consider the results of this study, as well as other ongoing research, in order to develop effective treatments for long-term COVID-19 symptoms. In the short term, investors may be cautious, as the study's findings could impact the stock prices of pharmaceutical companies that have invested heavily in Paxlovid. However, as more research becomes available, it is likely that new treatments and management strategies will emerge, providing hope for those affected by long-term COVID-19 symptoms.